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Abstract 
Annexins are Ca2+-regulated phospholipid-binding proteins that play an important role in the cell life cycle, exocyto-
sis, and apoptosis. Annexin A11 is one of the oldest vertebrate annexins that has a crucial role in sarcoidosis patho-
genesis. The mechanism of effect in sarcoidosis granuloma cells may be due to alterations in apoptosis. Immune cells 
with a specific mutation at protein location 230 are resistant to apoptosis and consequently have continued effects 
on inflammation and progression of sarcoidosis. The mechanism of action of annexin A11 may be based upon altera-
tions in delivering calcium to two different apoptosis pathways (caspase and P53).
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Background
Annexins (ANX) are a large family of calcium-dependent 
membrane-binding proteins. They are widely distrib-
uted among eukaryotes but largely absent in prokaryotes 
and yeasts. The first protein of this family, discovered in 
1977, was called synexin. Currently known as annexin 
A7, it caused aggregation of chromaffin granules in the 
adrenal glands in the presence of free calcium [1, 2]. The 
medulla of bovine adrenal glands was incubated with 
various concentrations of synexin and chromaffin gran-
ules [1]. The regions of contact between granules formed 
by this protein were structurally similar to the contacts 
seen between vesicles and the plasma membrane in the 
process of exocytosis. Because of this ability to bring 
granules together, Creutz and colleagues used the term 
“synexin” from the Greek synexis, which means “meet-
ing” [1]. The protein was found to be soluble, heat labile, 
and trypsin sensitive. Aggregation was also strongly tem-
perature dependent. It did not cause granule aggregation 
in the presence of magnesium, barium, or strontium, but 
was activated by calcium [1]. Further characterization of 
these calcium and phospholipid binding proteins showed 
that they were localized to many different types of cells 
and tissues. The proteins of one group (calpactins) were 
substrates for tyrosine kinases. Because of the similar 
membrane-binding properties of these molecules and 
their conserved amino acid sequences, Geisow and col-
leagues called the group “annexins” [3]. Annexins were 
found to be receptors for calcium in exocytosis, promot-
ing the close association of granules as well as the plasma 
membrane prior to secretion [4].
There is little information about annexin A11 and many 
of its structural and functional characteristics are specu-
lated based on similarity with other members of annexin 
family. Recently, genetic mutation in annexin A11 was 
linked to increasing susceptibility to sarcoidosis. It was 
also suggested that cells with mutant annexin A11 might 
have altered susceptibility to apoptosis. However, the 
mechanism of this effect has never been discussed. We 
propose here a molecular mechanism for this association.
Review
Annexin family
More than a 100 annexins have been identified in many 
different species [5]. Twelve proteins have been iden-
tified in humans; these are conventionally referred to 
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The descriptor ‘A’ denotes their presence in vertebrates; 
‘B’ denotes their presence in invertebrates; ‘C’ denotes 
their presence in fungi and some groups of unicellular 
eukaryotes; ‘D’ denotes their presence in plants; and ‘E’ 
their presence in protists [5, 6]. The zebrafish demon-
strates that the annexins are conserved through develop-
ment. Zebrafish have eleven annexin genes [7] that are 
expressed in many tissues during embryonic and larval 
stages. Aligning the zebrafish ANX genes with mamma-
lian ANX genes shows that three zebrafish ANX genes 
are homologous with human ANX1; two are homolo-
gous with human ANX2; and two are homologous with 
human ANX11. This information suggests that zebrafish 
ANX genes may have resulted from duplications after the 
divergence of the zebrafish and mammalian genomes [7].
Human annexin genes
The 12 human annexin genes range in size from 15  kb 
(ANXA9) to 96 kb (ANXA10) and are spread throughout 
the genome on chromosomes 1, 2, 4, 5, 8, 9, 10, and 15 
[6]. Other vertebral annexin genes may vary slightly in 
size and chromosomal linkage, but orthologues are simi-
lar in their sequence and splicing patterns. It is important 
that some annexin genes have been lost or duplicated in 
certain species, such as bony fish and pseudotetraploid 
frogs [8]. The duplication of annexin genes is also seen 
in humans [9]. Annexin A6 is a compound gene, prob-
ably derived from the fusion of duplicated ANXA5 and 
ANXA10 genes in early vertebrate evolution. The reasons 
for the annexin genes or their chromosomal regions to 
duplicate are not well understood. Their successful pres-
ervation and the extent to which they contribute to ver-
tebrate complexity are also not well described [10]. The 
presence of multiple members of the annexin family in 
all higher eukaryotes argues for their fundamental role in 
cell biology.
The ANXA11 gene is located on human chromosome 
10q22–q23 and is composed of 15 exons and 14 introns 
without the 5′ flanking region [11]. Exon 1 is the biggest 
region of the gene and is untranslated. The N-terminal is 
coded by exons 2 through 5; exons 6–15 are responsible 
for the C-terminal.
Annexin gene expression levels within human organs 
have a broad range, from universal (for example, annex-
ins A1, A2, A4, A5, A6, A7, and A11) to selective, such 
as annexin A3 in neutrophils, annexin A8 in the pla-
centa and skin, annexin A9 in the tongue, annexin A10 
in the stomach and annexin A13 in the small intestine 
[6]. ANXA11 has the highest gene expression in whole 
blood cells, particularly CD19+ cells (B-cells), CD14+ 
cells (monocytes) and CD33+ cells (myeloid). However, it 
is found in almost all tissues including lung, heart, and 
intestines [12]. Finding high expression of annexin A11 
macrophages [13], neutrophils [14] and T-cells [15] sug-
gests it may have a significant role in immune system 
function and possibly in a number of autoimmune dis-
eases (Fig. 1).
High expression patterns of annexins are detected 
in thymus, lung, and smooth muscle, and low expres-
sion patterns are found in testis, adrenal glands, and 
brain. The expression of annexins may change with the 
cell cycle. For instance, while the cell cycle progresses, 
the distribution of annexin A11 changes. This may be 
because it is associated with microtubules, vesicle traf-
ficking, and Ca2+ regulated exocytosis [1, 16, 17].
Protein structures
All annexins share a conserved C-terminal core domain 
made up of at least four similar repeats, each about 70 
amino acids long [18]. These subunits usually contain 
characteristic ‘type 2′ calcium binding sites. The number 
and location of these sites generally vary between differ-
ent annexin families, with variation and replacement with 
other motifs [5, 19]. Calcium-independent annexin mem-
brane interactions involve a switch from a helix-loop-
helix motif to the transmembrane helix, which drives 
a reversible membrane insertion. This pH-dependent 
conformation switch can be induced by the protonation 
of certain carboxylate residues found close to the loop 
of the helix-loop-helix motif. This model may explain 
why annexins can span a lipid bilayer [5]. In contrast to 
the core domain, individual vertebrate annexins have a 
unique N-terminal domain of variable length, amino acid 
sequences, and determinants of hydrophobicity. This 
plays an important role in mediating the interaction of 
annexins with other intracellular protein partners, such 
as those of the S100 family cytoplasmic proteins [20]. The 
NH2-terminal domain of annexin A2 forms a protein-
protein interaction through a highly specific binding site 
for the small dimeric S100 protein S100A10 [21]. This 
heterotetrameric complex is formed when two annexin 
A2 molecules are non-covalently linked via a S100A10 
dimer bound to their NH2-terminal domains. As a result, 
this complex can bind simultaneously to two membrane 
surfaces through its two annexin A2 cores [5].
Nonhuman annexin protein structure has also been 
studied. The simplest organisms known to express annex-
ins are the protist Giardia lamblia and the fungus Neuro-
spora crassa. The structure of nonhuman annexin protein 
was discussed elsewhere [22, 23]. Plant annexins have a 
structure that is distinct from vertebrates. They lack the 
variable N-terminal domains and type II calcium binding 
sites [24].
ANXA11 contains 504 amino acids and has a molecular 
weight of 56 kDa [25]. Its primary structure was purified 
from rabbit lung in 1992 [26]. ANXA11 has a C-terminal 
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core and a N-terminal head with 50  % homology with 
other annexin core domains [27]. The C-terminal core 
contains four domains with calcium binding properties 
(Fig. 2). Although ANXA11 has not been crystallized yet, 
its tertiary structure was predicted by information from 
ANXA1 and ANXA5 [28]. Three isoforms of Annexin 
A11 are identified in humans, but only one is expressed 
in cells [29].
Intracellular location and function of annexins
Annexins are usually cytosolic proteins with a soluble 
and a stable form. Annexins are reversibly associated 
with components of the cytoskeleton or proteins that 
mediate interactions between the cell and the extracellu-
lar matrix (matri-cellular proteins). Some annexins, such 
as annexins A11 and A2, have been found in the nucleus 
under particular circumstances in the cell cycle [16, 17]. 
It seems that annexin A2 works with annexin A11 in 
the nucleus. When annexin A2 enters the nucleus, it is 
rapidly exported to a functional nuclear export (NES) 
sequence that overlaps the p11-binding region in the 
annexin 11 N-terminus [21]. When p11 binds to annexin 
11, the complex is sequestered in the cytoplasmic com-
partment [16, 21].
In some circumstances, annexins can be expressed at 
the cell surface even without a secretory signal peptide. 
For example, annexin A1 translocates from the cytosol to 
Fig. 1 Tissue distribution of annexin A11 gene expression adapted from BioGPS website available at: http://biogps.org/#goto=genereport&id=311
Fig. 2 Model of the annexin A11 secondary structure with four core 
domains and a rich tail
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the cell surface following exposure of cells to glucocor-
ticoids [30]. In a study involving U-937 cells, annexin 1 
translocated from the intracellcular compartment to the 
cell membrane without a signal exporting sequence. The 
level of expression of annexin 1 was directly related to the 
time exposed to dexamethasone. Prior to its release, the 
protein may accumulate in the cell membrane, and this 
is stimulated by dexamethasone in differentiated U-937 
cells [30].
Annexin A2 expression at surface of vascular endothe-
lial cells has a function in the regulation of plasmin 
generation [31]. It has been shown that Annexin A2 is 
a co-receptor for tissue plasminogen activator and plas-
minogen. This expression can be found on a variety of 
cells, including endothelial cells, tumor cells, and mac-
rophages. This study also showed that Annexin A2 may 
also have a role in maintaining vascular patency and the 
cell formation of new blood vessels [31].
Annexin A11 distribution changes per cell cycle. It 
is more prevalent in the nucleus than the cytoplasm in 
interphase cells and then moves to degenerating nuclear 
envelope. And finally during the mitotic phase, it will be 
concentrated within the central spindle [16]. It has been 
shown that Annexin A11 also has an essential role in the 
terminal phase of cytokinesis. Annexin A11 is recruited 
to the midbody in late telophase, and without Annexin 
A11, cells cannot establish a functional midbody. [32]. 
Instead, daughter cells remain connected by intercellular 
bridges. As a result, these cells without Annexin A11 do 
not complete cytokinesis and die by apoptosis [32].
Annexins interaction with other proteins
S100 proteins, which only express in vertebrates, are 
a well-known group of proteins that interact with the 
annexins. The functions of S100 proteins are diverse and 
include regulating actin and microtubule networks, pro-
moting cell survival and proliferation, calcium homeo-
stasis, and mediating muscle contraction. The complex 
of annexin A2-S100A10 interacts with several membrane 
ion channels, such as transient receptor like potential 
vanilloid type 5 and 6 channels (TRPV5 and TRPV6). The 
complex also interacts with cystic fibrosis conductance 
regulator protein (CFTR) and plays a role the regulation 
of these ion channels [33, 34]. It is clear that these pro-
teins are involved in a great number of intracellular pro-
cesses, such as membrane trafficking, organization, and 
functioning as extracellular local hormones.
Annexin A11 is involved in cellular apoptotic pro-
cesses. The N-terminal domain of ANXA11 contains 
binding sites that deliver Ca2+ to S100A6 and apoptosis-
linked gene2 (ALG-2) whose protein augments apoptosis. 
The significance of these interactions in the pathogenesis 
of sarcoidosis is discussed later in this article.
Association of annexin to diseases in laboratory animal 
models
Studies on knockout mice of annexin families show a 
diversity of functions among these proteins. Loss of 
ANXA1 causes changes in the inflammatory response 
and the effects of glucocorticoids [35]. In the ANXA1 
null mouse line, there was altered expression of other 
annexins as well as cyclooxygenase-2 and cytoplasmic 
phospholipase A2. In addition, there was an exaggerated 
response to the stimuli characterized by an increase in 
leukocyte emigration and IL-1β generation and a partial 
or complete resistance to the anti-inflammatory effects of 
glucocorticoids [35].
Data supports the role of annexin 2 as a regulator 
of cell surface plasmin generation, fibrin homeostasis, 
and neovascularization in laboratory mice models [36]. 
Homozygous annexin 2 knockout mice were studied, and 
they showed deposition of fibrin in the microvasculature. 
These null mice also had deficits in the clearance of arte-
rial thrombi and tissue plasminogen activator (T-PA)–
dependent plasmin generation at the endothelial cell 
surface. Also, annexin 2–deficient mice displayed prob-
lems with neovascularization of fibroblast growth factor–
stimulated cornea and of oxygen-primed neonatal retina 
[36].
Another study involved the formation of the ANXA7 
knockout mouse. The viability of the ANXA7 null mouse 
was compared to the heterozygous mouse [37]. The 
ANXA7 null mutation mouse was did not survive past 
embryonic day 10. This was due to cerebral hemorrhage. 
On the other hand, the heterozygous mouse, though only 
expressing low levels of ANXA7, was viable and able to 
reproduce [37].
Another study of ANXA7 null mutant mouse proposed 
ANXA7 function in the fusion of vesicles as a calcium 
channel [38]. Cardiomyocytes from adult ANXA7 null 
mice were studied. When stimulated with high frequen-
cies, the cells showed an altered cell shortening relation-
ship. Possibly through its role in calcium regulation, this 
study suggested a function for annexin A7 in electrome-
chanical coupling [38]. The other annexins knockouts 
need further investigation.
Association of annexin to human diseases
Annexins have essential roles in the pathogenesis or pro-
gression of many human diseases. Recent genetic stud-
ies discovered single nucleotide polymorphisms (SNPs) 
in the genomes of this group of proteins. In a study from 
India, annexin A2 gene SNP (rs7170178) was found to be 
associated with osteonecrosis in sickle cell patients [39]. 
The frequency of the ANXA2 gene polymorphism was 
higher in the sickle cell patients compared to controls. 
The SNP was also present in higher frequency in sickle 
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cell osteonecrosis patients than those without osteone-
crosis [39].
In another study from Japan, the annexin A5 gene 
polymorphism was found to be associated with recur-
rent pregnancy loss. The promoter region of the ANXA5 
gene was sequenced in 243 Japanese women with recur-
rent pregnancy loss and 119 fertile controls [40]. In a 
case control study for six common ANXA5 gene SNPs, 
the carrier frequency for the minor allele was signifi-
cantly higher in the pregnancy loss group [40]. For SNP5, 
women with this minor allele had a two-fold higher risk 
of fetal loss than non- carriers. Homozygotes for the 
SNP5 minor allele had a seven-fold higher risk of recur-
rent pregnancy loss [40].
Annexins are also associated with autoimmune disor-
ders. In rheumatoid arthritis, high extracellular annexin 
V levels initiates the production of annexin V autoan-
tibodies that may have a crucial role in pathogenesis of 
disease [41]. Systemic lupus may involve defective clear-
ance of dying cells, resulting in the exposure of nuclear 
antigens in the form of cellular debris or microparticles. 
These microparticles may contain antigens that trigger 
autoimmune processes. Lupus patients have decreased 
annexin V binding microparticles and an increase in 
annexin V non-binding microparticles [42].
Dysregulation of Annexin A11 has been found in 
cancer, cancer treatment, and diabetes [43]. For exam-
ple, Annexin A11 is directly involved in cell prolifera-
tion in ovarian cancer [44]. The knockdown of annexin 
A11 expression reduced cell proliferation and the abil-
ity of ovarian cancer cells to form a colony. Silencing of 
annexin A11 was also associated with cisplatin resistance 
in ovarian cancer cells. [44, 45]. ANXA2 is also involved 
in P53-mediated apoptosis of lung cancer cells [46]. It 
has been shown that drug-resistant small cell lung cancer 
cells highly express annexin A2. Thus, Annexin A2 may 
have a role in pathogenicity of drug resistance [47].
Some members of the annexin family may also be used 
as biomarkers and for clinical imaging. For example, 
ANXA1 was investigated as a potential serum biomarker 
for lung cancer. Lung cancer tissues exhibited higher 
expression of annexin A1 than normal tissues. In addi-
tion, increased serum annexin A1 was significantly asso-
ciated with pathologic grade and clinical stage of lung 
cancer patients [48]. Quantitative 99  mTc-annexin A5 
(qAnx5) imaging uses human annexin A5 radiolabeled 
for the visualization and measurement of apoptosis. This 
imaging is being investigated as an objective evaluation 
of apoptosis before and after cancer treatment. Annexin 
A5 may be used as clinical imaging marker for treatment 
response [49].
ANXA11 and sarcoidosis
Sarcoidosis is a systemic immune disorder with a charac-
teristic accumulation of epithelioid granulomas in many 
organs, such as the lungs, kidney, skin and eyes [50, 51]. 
Chronic sarcoidosis is disease activity lasting more than 
2 years [52, 53]. One of the consequences of chronic sar-
coidosis is pulmonary fibrosis [54]. Pulmonary fibrosis 
occurs in 20 % of patients and contributes significantly to 
morbidity and mortality among these patients [55–58].
Genetic instability and mutation in annexin A11 has 
been identified in single nucleotide polymorphisms in 
patients with sarcoidosis compared to control groups. 
Decreased activation of CD8+ and CD19+, immune 
cells involved in sarcoidosis, are proposed mechanisms 
for sarcoidosis [15]. In addition to the SNP discovery, 
sarcoidosis patients show an increase in neutrophil 
counts in bronchoalveolar lavage fluid. This has led to 
the investigation of annexin A11, which is important 
in cell division, apoptosis, and neutrophil function. 
In a study of more than 440,000 SNPs of 490 German 
patients with sarcoidosis, a series of genetic associa-
tions were detected compared with controls [15]. The 
strongest association signal maps to the ANXA11 
(annexin A11) gene on chromosome 10q22.3. A com-
mon nonsynonymous SNP (rs104955) was found to be 
strongly associated with sarcoidosis. As it is demon-
strated in Fig. 3, this SNP causes a substitution of argi-
nine with cysteine at position 230 (R230C). Although 
the mechanistic effect of this change has not been well 
defined, it appears to affect apoptosis and proliferation 
in sarcoidosis [15]. Fillerova and coworkers showed that 
peripheral blood mononuclear cell (PBMC) isolated 
from subjects with sarcoidosis who carried the ANXA11 
R230C SNP were more resistant to apoptosis than the 
wild genotype. This association was particularly promi-
nent in subjects with the TT ANXA11 phenotype [59]. 
The mechanism of this increasing resistance to apopto-
sis was not discussed. We theorize that ANXA11 with 
structural changes after SNP R230C loses all or part of 
its functionality. As mentioned above, ANXA11 carries 
4 calcium ions and delivers calcium to many intracel-
lular pathways. ANXA11 is involved in apoptosis in at 
least two known pathways. As shown in Fig. 4, ANXA11 
is involved in mitogen-activated protein kinase (MAPK) 
and P53 pathways. Mitogen-activated protein kinase 
pathways are involved in apoptosis in the setting of 
environmental stress [60]. The MAPK pathway acti-
vates caspase pathway via an ALG-2 protein that is Ca2+ 
dependent. Without calcium delivery from ANXA11 to 
ALG-2, the apoptosis via caspase pathway would not be 
activated [61].
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Wild protein ANXA11 
position 230 (R230C)  
ANXA11  rs1049550  
Core domains 
N-terminal proline-tyrosine-glycine rich region N-terminal proline-tyrosine-glycine rich region 
Core domains 
Ca+2Ca+2
Fig. 3 ANXA11 polymorphism in location 230. Created based on this article: Alejandra Tomas and Stephen E Moss J Biol Chem 2003, 278:20210–
20216
Fig. 4 The role of ANXA11 in apoptosis. ANXA11 with delivering calcium (ca2+) to ALG-2 in caspase pathway and s100A6 in P53 pathway promote 
apoptosis. Reproduced based on Satoh and coworkers paper [61]
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The second important protein involved in apopto-
sis is P53 [62]. P53 mediated apoptosis pathway starts 
with joining S100 A6 to P53 which needs Ca2+ delivery 
from ANXA11 [16]. Indeed, if ANXA11 R230C could 
not deliver calcium to ALG-2 and S100A6, the apoptosis 
would not occur. However, how could the substitution of 
arginine with cysteine make the protein dysfunctional? 
The possible mechanism could involve the disulfide 
bond between the two cysteine thiol groups. One group 
is native with a close distance to another non-native 
group, which comes from R230C. The two groups form 
a disulfide bridge. Disulfide bonds provide a mixed out-
come, either an increase or decrease in protein structure 
stability [63]. With a new cysteine in the structure of 
ANXA11 R230C, a non-native disulfide bridge is formed. 
This misfolds the protein and renders it nonfunction-
ing [64]. Figure 5 shows the third structures of disulfide 
bonds in ANXA11.
In the sarcoidosis lung, granulomas develop when the 
immune cells attempt to wall off an unknown antigen trig-
ger. These cells include macrophages, lymphocytes, and 
multinucleated giant cells. The granuloma can be effaced 
by apoptosis leaving only minor scar. Without apoptosis 
the inflammatory and granulomatous reaction continues. 
Patients with ANXA11 R230C cannot clear granulomas 
due to altered apoptosis and may have a higher risk of 
onset of sarcoidosis and poorer outcome (Fig. 6).
Pre‑clinical advances in annexin and sarcoidosis
Hofmann et al. were the first group of researchers to iden-
tify the association of ANXA11 with sarcoidosis [15]. More 
recent studies have confirmed that Annexin A11 and its 
regulation of apoptosis is a key genetic player in the devel-
opment of sarcoidosis. The latest in sarcoidosis genetics 
research uses genome mapping to determine gene variants 
associated with increased granuloma formation [65]. A 
2014 study of the Han Chinese population confirmed the 
potential role of ANXA11 SNPs in the genetic susceptibil-
ity to sarcoidosis. Investigators studied 15 potential loci 
and found significant differences between patients with 
sarcoidosis and healthy controls for 3 SNPs. They showed 
that rs1049550 presented a significant effect on disease 
phenotype (p  <  0.001). The T allele was an important 
protective factor against sarcoidosis. Whereas carriers of 
rs1049550, the C allele, had a higher susceptibility to sar-
coidosis. This was confirmed in association analysis, which 
showed that the T–C haplotype occurred significantly less 
frequently and the C–C haplotypes occurred more fre-
quently in in patients with sarcoidosis [66].
Fig. 5 The 3rd structure of disulfide bonds in ANXA11. Modeled 
using Disulfide Bonds in Proteins (MODIP, http://caps.ncbs.res.in/
dsdbase/modip.html) and Disulfide by design (DbD, http://cptweb.
cpt.wayne.edu/DbD2/)
Fig. 6 Demonstrates our proposed mechanism of effect of ANXA11 rs1049550 in progression of sarcoidosis. a Shows onset of granuloma in wild 
type (above) and mutant type of ANXA11, b Shows regression of granulomatous reaction with apoptosis in wild type ANXA11 (above) and continu-
ation of granuloma with resistant to apoptosis in mutant type of ANXA11 (below). c Shows continuation of granuloma cause fibrosis changes in the 
mutant type of ANXA11
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In a 2013 study, the role of annexin A11 in sarcoidosis 
was confirmed in a US population. This association also 
extended to clinical manifestation of disease. The studied 
involved 1689 sarcoidosis cases and 1252 controls. 25 SNPs 
in and around ANXA11 were significantly associated with 
sarcoidosis risk in both African Americans and European 
Americans. The most significant allelic association was the 
minor C allele at rs1049550 among African and European 
Americans [67]. This was the same allele identified in the 
original study by Hofmann et al. [15]. ANXA11 mutations 
also conferred risk for radiographic expression of disease. 
For SNP rs4399277, the strongest association was found 
in cases with Scadding stage IV disease. The A allele was 
associated with a 1.52-fold increase in the odds of stage IV 
disease. New independent loci associated with sarcoidosis 
risk in ANXA11 were also identified. The minor A allele of 
SNP rs61860052 was associated with a protective effect on 
sarcoidosis in African Americans [67].
These recent advances of annexin A11 in the pre-clin-
ical stage show its significant role in the pathogenesis 
of sarcoidosis. In the era of personalized medicine, the 
annexin could be a novel focus. Annexin A11 thus may 
be a target for clinical trials in which a patient’s genetic 
risk factors are used to tailor treatment [65].
Conclusions
Annexins have significant effects on human health and 
disease. Annexin A11 affects two apoptosis related path-
ways (caspase and P53) and has a crucial role in sarcoido-
sis pathogenesis. This theory should be tested in cell 
culture and animal models. Recent studies show the sig-
nificant role of annexin A11 in the genetic susceptibility 
to sarcoidosis. If the ANXA11 could increase susceptibil-
ity to sarcoiodosis via interaction with caspase and P53, 
a new opportunity to develop new therapeutic targets in 
sarcoidosis will be recognized.
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